mass-spectrometry-2019-scientifictracks

8 / 8

Mass Spectrometry 2019
March 04-05, 2019
Berlin, Germany
Mass Spectrometry
9th Edition of International Conference on
International Journal of Drug Development and Research
ISSN: 0975-9344 Page 26
Lansoprazole and simvastatin reduces the ability
of clopidogrel to inhibit platelet aggregation in
patients undergoing percutaneous coronary
intervention in a tertiary health care system: a
prospective drug–drug interaction study
Jinesh B Nagavi1, Hanumanthachar Joshi 2, Bannimath Gurupadayya3 and
Preethi G A4
1,2Sarada Vilas College of Pharmacy, India
3JSS College of Pharmacy, JSS Academy, India
4Co-ordinator, HESDAR center, JSS Layout, Shakti Nagar, Mysuru, Karnataka, India
Clopidogrel, a prodrug is found to be less effective in
inhibiting the platelet aggregation when administered
along with PPI’s and statins in patients undergoing
cardiac stent, ST segment elevated Myocardial
infarction (STEMI) followed by percutaneous coronary
intervention (PCI). Clopidogrel binds to CYP2C19, a
hepatic enzyme to get converted to its active metabolite
in order to achieve desired pharmacological activity. The
cytochrome P450 3A4 which is partially involved in the
metabolism of clopidogrel also metabolizes PPIs like
omeprazole, lansoprazole and pantoprazole; statins,
mainly atorvastatin, rosuvastatin and simvastatin to the
greater extent. In the current study, patients on PPI’s
with dual antiplatelet therapy and patients on PPI’s and
statins with dual antiplatelet therapy are considered to
understand the potential drug–drug interactions (pDDI)
among the South Asian population. Platelet aggregation
was measured in 91 patients undergoing coronary artery
stent implantation treated with clopidogrel and aspirin
along with PPI’s and statins.
Itwasobserved that lansoprazoleandsimvastatin, but not
omeprazole, pantoprazole and atorvastatin, rosuvastatin,
inhibited the antiplatelet activity of clopidogrel. The
percent platelet aggregation was 81 ± 2 (p = 0.012), 72
± 6 (p = 0.001), and 43 ± 23 (p = 0.027) in the presence
of clopidogrel with lansoprazole, omeprazole and
pantoprazole respectively. Aggregation was found to be
91 ± 4 (p = 0.001), 51 ± 3 (p = 0.009) and 12 ± 23 (p =
0.031) in the presence of clopidogrel with atorvastatin
and rosuvastatin respectively.
A prominent drug–drug interaction was observed
with patients on dual antiplatelet therapy along with
lansoprazole and simvastatin.
Biography
Jinesh Bahubali Nagavi has completed his PhD in Analytical
Chemistry at JSS University. He has worked as an Instructor
and Lecturer at RAK Medical and Health Sciences University,
UAE. He has published more than 15 papers in reputed na-
tional and international peer reviewed journals, presented his
research work in more than 10 International & national con-
ferences. He has been serving as an Assistant Professor of
Pharmaceutical Chemistry at Sarada Vilas College of Pharma-
cy, RGUHS, Karnataka, India. Dr. Jinesh has special interest in
bioanalytical method development and validation with hyphen-
ated techniques, pre-clinical trials, drug interactions, pharma-
cokinetic studies and clinical research.
Jinesh B Nagavi, Int J Drug Dev & Res 2019, Volume 11
DOI: 10.21767/0975-9344-C1-005